clopidogrel + aspirin (MicroPort)

DAPT (Dual Antiplatelet Therapy) in this context refers to the combination of aspirin and clopidogrel, a regimen used to prevent thrombotic complications following percutaneous coronary intervention (PCI). This specific application is associated with Shanghai MicroPort Medical's TARGET SAFE trial, which compares a 1-month versus a 6-month DAPT duration in high bleeding risk (HBR) patients who have received the Firehawk sirolimus-eluting stent. Aspirin functions by irreversibly inhibiting cyclooxygenase-1 (COX-1), thereby blocking the production of thromboxane A2, a potent platelet activator. Clopidogrel is a thienopyridine prodrug that, once metabolized, irreversibly antagonizes the P2Y12 receptor on platelets, preventing ADP-induced aggregation. Together, these agents provide synergistic protection against stent thrombosis and myocardial infarction in patients with coronary artery disease.

Other names

DAPTDual Antiplatelet Therapy1 month DAPT6 months DAPT